SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Allied Corp. – ‘10-Q’ for 11/30/20

On:  Wednesday, 1/20/21, at 3:35pm ET   ·   For:  11/30/20   ·   Accession #:  1477932-21-338   ·   File #:  0-56002

Previous ‘10-Q’:  ‘10-Q’ on 7/15/20 for 5/31/20   ·   Next:  ‘10-Q’ on 4/15/21 for 2/28/21   ·   Latest:  ‘10-Q’ on 4/19/24 for 2/29/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/20/21  Allied Corp.                      10-Q       11/30/20   79:3.5M                                   Discount Edgar/FA

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    382K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
12: R1          Cover                                               HTML     51K 
13: R2          Condensed Consolidated Balance Sheets               HTML     81K 
14: R3          Condensed Consolidated Balance Sheets               HTML     37K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML     79K 
                and Comprehensive Loss (Unaudited)                               
16: R5          Condensed Consolidated Statements of Stockholders   HTML     52K 
                Equity (Unaudited)                                               
17: R6          Condensed Consolidated Statements of Cash Flows     HTML     84K 
                (Unaudited)                                                      
18: R7          Nature of operations, reverse take-over             HTML     37K 
                transaction and going concern                                    
19: R8          Significant accounting policies                     HTML     68K 
20: R9          Reverse acquisition transaction                     HTML     23K 
21: R10         Deposits and advances                               HTML     28K 
22: R11         Property plant and equipment                        HTML     49K 
23: R12         Intangible assets                                   HTML     31K 
24: R13         Leases                                              HTML     41K 
25: R14         Loans payable                                       HTML     22K 
26: R15         Convertible Notes                                   HTML     46K 
27: R16         Equity                                              HTML     24K 
28: R17         Related party transactions and balances             HTML     32K 
29: R18         Financial risk factors                              HTML     35K 
30: R19         Capital management                                  HTML     22K 
31: R20         Commitments and contingencies                       HTML     27K 
32: R21         Share purchase warrants                             HTML     31K 
33: R22         Non-cash activities                                 HTML     26K 
34: R23         Segment disclosure                                  HTML     33K 
35: R24         Subsequent events                                   HTML     22K 
36: R25         Significant accounting policies (Policies)          HTML     94K 
37: R26         Significant accounting policies (Tables)            HTML     23K 
38: R27         Deposits and advances (Tables)                      HTML     27K 
39: R28         Property plant and equipment (Tables)               HTML     44K 
40: R29         Intangible assets (Tables)                          HTML     29K 
41: R30         Leases (Tables)                                     HTML     38K 
42: R31         Related party transactions and balances (Tables)    HTML     29K 
43: R32         Financial risk factors (Tables)                     HTML     28K 
44: R33         Share purchase warrants (Tables)                    HTML     32K 
45: R34         Noncash activities (Tables)                         HTML     25K 
46: R35         Segment disclosure (Tables)                         HTML     34K 
47: R36         Nature of operations reverse takeover transaction   HTML     39K 
                and going concern (Details Narrative)                            
48: R37         Significant accounting policies (Details)           HTML     25K 
49: R38         Significant accounting policies (Details            HTML     26K 
                Narrative)                                                       
50: R39         Reverse acquisition transaction (Details            HTML     26K 
                Narrative)                                                       
51: R40         Deposits and advances (Details)                     HTML     27K 
52: R41         Deposits and advances (Details Narrative)           HTML     30K 
53: R42         Property plant and equipment (Details)              HTML     54K 
54: R43         Intangible assets (Details)                         HTML     32K 
55: R44         Intangible assets (Details Narrative)               HTML     23K 
56: R45         Leases (Details)                                    HTML     26K 
57: R46         Leases (Details 1)                                  HTML     22K 
58: R47         Leases (Details 2)                                  HTML     27K 
59: R48         Leases (Details 3)                                  HTML     40K 
60: R49         Leases (Details Narrative)                          HTML     35K 
61: R50         Loans payable (Details Narrative)                   HTML     30K 
62: R51         Convertible Note (Details Narrative)                HTML    128K 
63: R52         Equity (Detail Narrative)                           HTML     32K 
64: R53         Related party transactions and balances (Details)   HTML     21K 
65: R54         Related party transactions and balances (Details    HTML     28K 
                1)                                                               
66: R55         Related party transactions and balances (Details    HTML     24K 
                Narrative)                                                       
67: R56         Financial risk factors (Details)                    HTML     29K 
68: R57         Financial risk factors (Details 1)                  HTML     26K 
69: R58         Financial risk factors (Details Narrative)          HTML     28K 
70: R59         Commitments and contingencies (Details Narrative)   HTML     47K 
71: R60         Share purchase warrants (Details)                   HTML     33K 
72: R61         Share purchase warrants (Details 1)                 HTML     35K 
73: R62         Noncash activities (Details)                        HTML     26K 
74: R63         Segment disclosure (Details)                        HTML     39K 
75: R64         Segment disclosure (Details 1)                      HTML     28K 
76: R65         Subsequent events (Details Narrative)               HTML     27K 
78: XML         IDEA XML File -- Filing Summary                      XML    140K 
77: EXCEL       IDEA Workbook of Financial Reports                  XLSX     83K 
 6: EX-101.INS  XBRL Instance -- alid-20201130                       XML    881K 
 9: EX-101.CAL  XBRL Calculations -- alid-20201130_cal               XML    139K 
11: EX-101.DEF  XBRL Definitions -- alid-20201130_def                XML    405K 
 8: EX-101.LAB  XBRL Labels -- alid-20201130_lab                     XML    704K 
10: EX-101.PRE  XBRL Presentations -- alid-20201130_pre              XML    637K 
 7: EX-101.SCH  XBRL Schema -- alid-20201130                         XSD    178K 
79: ZIP         XBRL Zipped Folder -- 0001477932-21-000338-xbrl      Zip    106K 


‘10-Q’   —   Quarterly Report
Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Table of Contents
"Part I-Financial Information
"Item 1
"Financial Statements
"Condensed consolidated interim balance sheets at November 30, 2020 (unaudited) and August 31, 2020
"Condensed consolidated interim statements of operations and comprehensive loss for the three months ended November 30, 2020 and 2019 (unaudited)
"Condensed consolidated interim statement of stockholders' equity for the three months ended November 30, 2020 and 2019 (unaudited)
"Condensed consolidated interim statement of cash flows for the three months ended November 30, 2020 and 2019 (unaudited)
"Notes to the unaudited condensed consolidated interim financial statements
"Item 2
"Management's Discussion and Analysis of Financial Condition and Results of Operations
"Item 3
"Quantitative and Qualitative Disclosures About Market Risk
"Item 4
"Controls and Procedures
"Part Ii-Other Information
"Legal Proceedings
"Item 1A
"Risk Factors
"Unregistered Sales of Securities and Use of Proceeds
"Defaults Upon Senior Securities
"Mining Safety Disclosure
"Item 5
"Other Information
"Item 6
"Exhibits

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  

For the quarterly period ended November 30, 2020

 

Commission File Number 000-56002

 

ALLIED CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

33-1227173

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

1405 St. Paul St., Suite 201, Kelowna, BC, Canada V1Y 9N2

(Address of principal executive offices) (Zip Code)

 

877-255-4337

(Registrant’s telephone number, including area code)

 

_____________________________________________

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes   ☐ No

 

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes   ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes   ☒ No

 

As of November 30, 2020, there were 85,305,780 shares of common stock issued and outstanding.

  

 

 

TABLE OF CONTENTS

 

PART I—FINANCIAL INFORMATION

 

 

 

 

 

Item 1.

Financial Statements.

3

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

29

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

38

 

Item 4.

Controls and Procedures.

38

 

 

 

PART II—OTHER INFORMATION

 

 

 

 

 

Item 1.

Legal Proceedings.

39

 

Item 1A.

Risk Factors.

40

 

Item 2.

Unregistered Sales of Securities and Use of Proceeds.

40

 

Item 3.

Defaults Upon Senior Securities.

40

 

Item 4.

Mining Safety Disclosure.

40

 

Item 5.

Other Information.

40

 

Item 6.

Exhibits.

41

 

 

 
2

Table of Contents

  

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

ALLIED CORP.

CONSOLIDATED FINANCIAL STATEMENTS

 

Condensed consolidated interim balance sheets at November 30, 2020 (unaudited) and August 31, 2020

 

4

 

 

 

 

 

Condensed consolidated interim statements of operations and comprehensive loss for the three months ended November 30, 2020 and 2019 (unaudited)

 

5

 

 

 

 

 

Condensed consolidated interim statement of stockholders’ equity for the three months ended November 30, 2020 and 2019 (unaudited)

 

6

 

 

 

 

 

Condensed consolidated interim statement of cash flows for the three months ended November 30, 2020 and 2019 (unaudited)

 

7

 

 

 

 

 

Notes to the unaudited condensed consolidated interim financial statements

 

8

 

 

 
3

Table of Contents

   

ALLIED CORP.

Condensed Consolidated Balance Sheets

(Expressed in US Dollars)

 

 

 

November 30,

2020

 

 

August 31,

2020

 

 

 

(Unaudited)

 

 

 

Assets

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

$ 11,395

 

 

$ 94,047

 

Inventory

 

 

60,486

 

 

 

52,585

 

Prepaid expenses (Note 12 (b))

 

 

21,486

 

 

 

51,682

 

Total current assets

 

 

93,367

 

 

 

198,314

 

 

 

 

 

 

 

 

 

 

Deposits and advances (Note 4)

 

 

2,836,972

 

 

 

3,008,246

 

Right-of-use assets (Note 7)

 

 

74,619

 

 

 

374,997

 

Property, plant and equipment (Note 5)

 

 

248,374

 

 

 

223,020

 

Intangible assets (Note 6)

 

 

3,279,833

 

 

 

3,300,000

 

Total assets

 

$ 6,533,165

 

 

$ 7,104,577

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$ 1,475,174

 

 

$ 1,396,495

 

Current portion of lease liabilities (Note 7)

 

 

3,972

 

 

 

17,073

 

Loan payable (Note 8)

 

 

1,253,772

 

 

 

1,253,772

 

Convertible notes payable (Note 9)

 

 

455,484

 

 

 

400,000

 

Total current liabilities

 

 

3,188,402

 

 

 

3,067,340

 

 

 

 

 

 

 

 

 

 

Lease liabilities, net of current portion (Note 7)

 

 

70,647

 

 

 

333,073

 

Total liabilities

 

$ 3,259,049

 

 

$ 3,400,413

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Preferred stock – 50,000,000 shares authorized, $0.0001 par value Nil shares issued and outstanding

 

$ -

 

 

$ -

 

Common stock – 300,000,000 shares authorized, $0.0001 par value; 85,305,780 shares issued and outstanding (85,105,780 – par value $0.0001 – August 31, 2020)

 

 

8,531

 

 

 

8,511

 

Additional paid in capital

 

 

12,763,253

 

 

 

12,226,382

 

Common stock issuable (Note 10)

 

 

129,952

 

 

 

19,952

 

Accumulated deficit

 

 

(9,104,428 )

 

 

(7,908,566 )

Accumulated other comprehensive loss

 

 

(523,192 )

 

 

(642,115 )

 

 

 

 

 

 

 

 

 

Total stockholders’ equity

 

 

3,274,116

 

 

 

3,704,164

 

Total liabilities and stockholders’ equity

 

$ 6,533,165

 

 

$ 7,104,577

 

 

Nature of operations and going concern (Note 1)

Commitments (Note 14)

Subsequent events (Note 18)

 

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

 

 
4

Table of Contents

  

ALLIED CORP.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Expressed in US dollars)

(Unaudited)

 

 

 

For the Three

Months Ended

November 30,

2020

 

 

For the Three

Months Ended

November 30,

2019

 

 

 

$

 

 

$

 

 

 

 

 

 

 

 

Revenue

 

 

4,200

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

Amortization

 

 

169,680

 

 

 

-

 

Charitable donations

 

 

-

 

 

 

73,289

 

Consulting fees

 

 

327,843

 

 

 

174,140

 

Foreign exchange

 

 

(4,965 )

 

 

(71,134 )

Interest expense

 

 

112,840

 

 

 

-

 

Office and miscellaneous

 

 

105,812

 

 

 

80,971

 

Professional expenses

 

 

130,631

 

 

 

146,548

 

Rent

 

 

20,832

 

 

 

4,329

 

Research and development

 

 

-

 

 

 

8,009

 

Travel

 

 

1,341

 

 

 

42,015

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

864,014

 

 

 

458,167

 

Loss before other expenses

 

 

(859,814 )

 

 

(458,167 )

Other expenses

 

 

 

 

 

 

 

 

Loss on termination of lease

 

 

(65,565 )

 

 

-

 

Settlement payments (Note 14)

 

 

(105,000 )

 

 

 

 

Loss on extinguishment of convertible debt

 

 

(110,000 )

 

 

-

 

Accretion of convertible debt

 

 

(55,483 )

 

 

-

 

Total other expenses

 

 

(336,048 )

 

 

-

 

Net loss

 

 

(1,195,862 )

 

 

(458,167 )

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

118,923

 

 

 

(5,680 )

 

 

 

 

 

 

 

 

 

Comprehensive loss

 

 

(1,076,939 )

 

 

(463,847 )

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share

 

 

(0.01 )

 

 

(0.01 )

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

 

85,163,802

 

 

 

79,299,685

 

 

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

 

 
5

Table of Contents

 

ALLIED CORP.

Condensed Consolidated Statements of Stockholders’ Equity

(Expressed in US dollars)

(Unaudited)

 

 

 

Common stock

 

 

Additional

 

 

 

 

 

Stock

 

 

 

 

 

Accumulated Other

 

 

 

 

 

 

Number of shares

 

 

Amount

 

 

Paid in

Capital

 

 

Stock

issuable

 

 

subscription receivable

 

 

Accumulated Deficit

 

 

Comprehensive Loss

 

 

Total

 

 

 

 

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

Balance, August 31, 2019

 

 

51,200,014

 

 

 

5,120

 

 

 

912,965

 

 

 

24,135

 

 

 

(364 )

 

 

(1,300,803 )

 

 

(30,491 )

 

 

(389,438 )

Cancellation of common stock

 

 

(10,459,220 )

 

 

(1,046 )

 

 

1,046

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Effect of reverse acquisition

 

 

42,027,986

 

 

 

4,203

 

 

 

3,925,542

 

 

 

65,092

 

 

 

364

 

 

 

-

 

 

 

-

 

 

 

3,995,201

 

Common stock subscribed

 

 

-

 

 

 

-

 

 

 

 

 

 

 

275,908

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

275,908

 

Comprehensive loss for the period

 

 

-

 

 

 

-

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

(458,167 )

 

 

(5,680 )

 

 

(463,847 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, November 30, 2019

 

 

82,768,780

 

 

 

8,277

 

 

 

4,839,553

 

 

 

365,135

 

 

 

-

 

 

 

(1,758,970 )

 

 

(36,171 )

 

 

3,417,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

Additional

 

 

 

 

 

Stock

 

 

 

 

 

Accumulated Other

 

 

 

 

 

 

Number of shares

 

 

Amount

 

 

Paid in

Capital

 

 

Stock

issuable

 

 

subscription receivable

 

 

Accumulated

Deficit

 

 

Comprehensive Income (Loss)

 

 

Total

 

 

 

 

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

Balance, August 31, 2020

 

 

85,105,780

 

 

 

8,511

 

 

 

12,226,382

 

 

 

19,952

 

 

 

-

 

 

 

(7,908,566 )

 

 

(642,115 )

 

 

3,704,164

 

Shares issued for cash

 

 

200,000

 

 

 

20

 

 

 

249,980

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

250,000

 

Beneficial conversion feature of convertible notes

 

 

-

 

 

 

-

 

 

 

153,764

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

153,764

 

Detachable warrants issuable with convertible notes

 

 

-

 

 

 

-

 

 

 

133,127

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

133,127

 

Shares issuable as consideration for extinguishment of convertible notes

 

 

-

 

 

 

-

 

 

 

 

 

 

 

110,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

110,000

 

Comprehensive loss for the period

 

 

-

 

 

 

-

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

(1,195,862 )

 

 

118,923

 

 

 

(1,076,939 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, November 30, 2020

 

 

85,305,780

 

 

 

8,531

 

 

 

12,763,253

 

 

 

129,952

 

 

 

-

 

 

 

(9,104,428 )

 

 

(523,192 )

 

 

3,274,116

 

 

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

 

 
6

Table of Contents

 

ALLIED CORP.

Condensed Consolidated Statements of Cash Flows

(Expressed in US dollars)

(Unaudited)

 

 

 

For the Three Months Ended November 30, 2020

 

 

For the Three Months Ended November 30, 2019

 

 

 

$

 

 

$

 

Cash provided by (used in):

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

Net loss for the period

 

 

(1,195,862 )

 

 

(458,167 )

Adjustment to net loss for the period for non-cash items

 

 

 

 

 

 

 

 

Accretion of convertible notes

 

 

55,483

 

 

 

-

 

Loss on extinguishment of convertible notes

 

 

110,000

 

 

 

-

 

Loss on termination of lease

 

 

65,565

 

 

 

-

 

Amortization

 

 

169,680

 

 

 

-

 

Changes in non-cash working capital balance:

 

 

 

 

 

 

 

 

Increase in accounts receivable

 

 

-

 

 

 

(79,069 )

Decrease (increase) in prepaid expenses

 

 

41,922

 

 

 

(4,208 )

Increase in due from related parties

 

 

(11,726 )

 

 

(16,470 )

Increase in accounts payable and accrued liabilities

 

 

78,679

 

 

 

42,233

 

Increase in inventory

 

 

(7,901 )

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

(694,160 )

 

 

(515,681 )

Investing activities

 

 

 

 

 

 

 

 

Purchase of property plant & equipment

 

 

(21,932 )

 

 

-

 

Refund of deposits (payments) on acquisition of assets

 

 

129,897

 

 

 

(493,488 )

Cash acquired from asset acquisition

 

 

-

 

 

 

12,894

 

 

 

 

107,965

 

 

 

(480,594 )

Financing activities

 

 

 

 

 

 

 

 

Proceeds of convertible note

 

 

286,892

 

 

 

-

 

Repayment of finance lease obligations

 

 

(12,480 )

 

 

-

 

Proceeds from the issuance of common stock

 

 

250,000

 

 

 

276,000

 

 

 

 

524,412

 

 

 

276,000

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate on changes on cash

 

 

(20,869 )

 

 

(387 )

Change in cash

 

 

(82,652 )

 

 

(720,662 )

Cash, beginning of period

 

 

94,047

 

 

 

1,080,882

 

Cash, end of period

 

 

11,395

 

 

 

360,220

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow disclosures:

 

 

 

 

 

 

 

 

Income taxes paid

 

 

-

 

 

 

-

 

Interest paid

 

 

112,840

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Non-cash activities (Note 16)

 

 

 

 

 

 

 

 

 

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

 

 
7

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

1.

Nature of operations, reverse take-over transaction and going concern

 

 

 

 

a)

Nature of operations

 

 

 

 

 

Allied Corp. (the “Company or Allied”) was incorporated in the State of Nevada on February 3, 2013. On July 1, 2019, the Company changed its name to Allied Corp.

 

 

 

 

 

The Company’s business plan is to discover new medical technologies some of which are cannabis derived to target full scope therapy and support for trauma survivors, military veterans and first responders, however the Company has not begun any operations or obtained the required permits to begin operations. The head office and the registered office of the Company are located at 1405 St. Paul Street, Kelowna BC V1Y 2E4.

 

 

 

 

 

On September 10, 2019, the Company was acquired in a reverse takeover (“RTO”) transaction (see Note 1b) and the RTO is considered a purchase of the Company’s net assets (see Note 3) by AM (Advanced Micro) Biosciences, Inc. (“AM Biosciences”). For accounting purposes, the legal subsidiary, AM Biosciences has been treated as the acquirer and Allied Corp., the legal parent, has been treated as the acquiree.

 

 

 

 

 

On February 18, 2020, the Company acquired all the issued and outstanding share capital of a Colombian company, Allied Colombia S.A.S (formerly Medicolombia’s Cannabis S.A.S) (“Medicolombia”).

 

 

 

 

b)

Reverse take-over transaction (RTO)

 

 

 

 

 

On July 25, 2019, as amended effective August 27, 2019, the Company entered into a reorganization and stock purchase agreement (the “Reorganization Agreement”) to acquire 100% of the issued and outstanding equity of AM (Advanced Micro) Biosciences, Inc (“AM Biosciences”). Effective September 10, 2019, the parties closed the Reorganization Agreement (the “Acquisition”). As part of the transaction, Pacific Capital Investment Group, Inc., the then majority shareholder of Allied (the “Allied Shareholder”) delivered 51,200,014 shares of common stock, representing approximately 65.42% of the outstanding equity of Allied Corp. to SECFAC Exchange Corp. on behalf of the prior shareholders of AM Biosciences and certain other designees of AM Biosciences as a consideration to acquire 100% of the issued and outstanding equity of AM Biosciences. Further, as part of the transaction, the Allied Shareholder submitted for cancellation and return to treasury 10,459,220 and 4,500,000 shares of common stock. As a consequence, immediately subsequent to the close of the Reorganization Agreement, Allied had 78,268,780 shares of common stock outstanding.

 

 

 

 

 

The Reorganization Agreement constitutes a reverse merger, such that AM Biosciences acquired control of Allied Corp. At the time of the Reorganization Agreement, the operations of Allied Corp. did not constitute businesses under ASC 805 Business Combinations and accordingly the transaction is considered a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). Under this method of accounting, AM Biosciences was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the acquisition: (i) AM Biosciences’ stockholders owned a substantial majority of the voting rights in the combined company, (ii) AM Biosciences designated a majority of the members of the initial board of directors of the combined company, and (iii) AM Biosciences’ senior management holds all key positions in the senior management of the combined company. As a result, as of the closing date of the acquisition, the net assets of the Company were recorded at their acquisition-date relative fair values in the consolidated financial statements of the Company and the reported operating results prior to the acquisition will be those of AM Biosciences. See Note 3 for details on the reverse acquisition.

 

 
8

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

1.

Nature of operations, reverse take-over transaction and going concern (continued)

 

 

 

 

c)

Going concern

 

 

 

 

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company incurred a net loss for the three months ended November 30, 2020 of $1,195,862, has generated minimal revenue and as at November 30, 2020 has a working capital deficit of $3,095,035. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise sufficient financing to acquire or develop a profitable business. Management intends on financing its operations and future development activities largely from the sale of equity securities with some additional funding from other traditional financing sources, including related party loans until such time that funds provided by future planned operations are sufficient to fund working capital requirements, refer to note 14 for details.

 

 

 

 

d)

COVID-19 impact

 

 

 

 

 

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak and the related adverse public health developments have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. Management has determined that there has been no significant impact to the Company’s operations, however management continues to monitor the situation.

 

 

 

 

e)

Business Risks

 

 

 

 

 

While some states in the United States have authorized the use and sale of cannabis, it remains illegal under federal law and the approach to enforcement of U.S. federal laws against cannabis is subject to change. Because the Company plans to engage in cannabis-related activities in the United States, it assumes certain risks due to conflicting state and federal laws. The federal law relating to cannabis could be enforced at any time and this would put the Company at risk of being prosecuted and having its assets seized.

 

 

 

 

 

On January 4, 2018, United States Attorney General Jeff Sessions issued a memorandum to United States district attorneys (the ““Sessions Memorandum”) which rescinded previous guidance from the United States Department of Justice specific to cannabis enforcement in the United States, including the Cole Memorandum. With the Cole Memorandum rescinded, United States federal prosecutors no longer have guidance relating to the exercise of their discretion in determining whether to prosecute cannabis related violations of United States federal law. In response to the Sessions Memorandum, on April 13, 2018, the United States President Donald Trump promised Colorado Senator Cory Gardner that he will support efforts to protect states that have legalized cannabis. Nevertheless, a significant change in the federal government’s enforcement policy with respect to current federal laws applicable to cannabis could cause significant financial damage to the Company. The Company may be irreparably harmed by a change in enforcement policies of the federal government depending on the nature of such change.

 

 

 

 

 

Given the current illegality of cannabis under United States federal law, the Company’s ability to access both public and private capital may be hindered by the fact that certain financial institutions are regulated by the United States federal government and are thus prohibited from providing financing to companies engaged in cannabis related activities. The Company’s ability to access public capital markets in the United States is directly hindered as a result. The Company may, however, be able to access public and private capital markets in Canada in order to support continuing operations.

 

 
9

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

2.

Significant accounting  policies

 

 

 

 

Business Presentation

 

 

 

 

These unaudited condensed consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and are expressed in United States dollars. The Company’s fiscal year end is August 31.

 

 

 

 

These interim unaudited financial statements have been prepared in accordance with US GAAP for interim financial information and with the instructions to Securities and Exchange Commission (“SEC”) Form 10-Q. They do not include all of the information and footnotes required by US GAAP for complete financial statements. Therefore, these interim financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended August 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC.

 

 

 

 

The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at November 30, 2020, and the results of its operations for the three months ended November 30, 2020 and cash flows for the three months ended November 30, 2020. The results of operations for the period ended November 30, 2020 are not necessarily indicative of the results to be expected for future quarters or the full year.

 

 

 

 

The significant accounting policies followed are:

 

 

 

 

a)

Principles of consolidation

 

 

 

 

 

The consolidated financial statements include accounts of Allied Corp. and its majority owned subsidiaries. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.

 

 

 

 

b)

Cash and cash equivalents

 

 

 

 

 

Cash is comprised of cash on hand, cash held in trust accounts and demand deposits. Cash equivalents are short-term, highly liquid investments with maturities within three months when acquired. The Company did not have any cash equivalents as of November 30, 2020 and August 31, 2020.

 

 

 

 

c)

Property, plant and equipment

 

 

 

 

 

Property, plant and equipment are stated at cost. The Company depreciates the cost of property and equipment over their estimated useful lives at the following annual rates and methods:

     

Equipment

10 years straight-line basis

Office and computer equipment

5 years straight-line basis

Land equipment

10 years straight-line basis

  

 

d)

Inventory

 

 

 

 

 

Inventories are stated at the lower of cost or market. As of November 30, 2020 and August 31, 2020, the inventory consisted of containers and packaging materials.

 

 
10

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

2.

Significant accounting  policies (continued)

 

 

 

 

e)

Intangible assets

 

 

 

 

 

At November 30, 2020 and August 31, 2020, intangible assets include licenses which are being amortized over their estimated useful lives of 3-10 years. The Company’s licenses are amortized over their economic or legal life on a straight-line basis, whichever is shorter. The licenses have been amortized from the date of acquisition.

 

 

 

 

 

The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives.

 

 

 

 

 

For long-lived assets, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

 

 

 

 

f)

Long-lived assets

 

 

 

 

 

In accordance with ASC 360, Property, Plant and Equipment, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

 

 

 

 

g)

Foreign currency translation and functional currency conversion

 

 

 

 

 

Items included in these consolidated financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entities operate (the “functional currency”).

 

 

 

 

 

Prior to September 10, 2019, the Company’s functional currency was the Canadian dollar. Translation gains and losses from the application of the U.S. dollar as the reporting currency during the period that the Canadian dollar was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss.

 

 

 

 

 

The Company re-assessed its functional currency and determined as at September 10, 2019, its functional currency changed from the Canadian dollar to the U.S. dollar based on management’s analysis of changes in our organization. The change in functional currency was accounted for prospectively from September 10, 2019 and prior period financial statements were not restated for the change in functional currency.

 

 
11

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

2.

Significant accounting  policies (continued)

 

 

 

 

 

For periods commencing September 10, 2019, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets and non-monetary liabilities incurred after September 10, 2019 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transactions. Foreign exchange gains and losses are included in the statement of operations and comprehensive loss as foreign exchange gains.

 

 

 

 

 

The Company assessed the functional currency for MediColombia, a wholly-owned subsidiary acquired by the Company on February 18, 2020 to be the Colombian peso. This company has now changed its name to Allied Colombia S.A.S.

 

 

 

 

 

The functional currency for Tactical Relief LLC is U.S. dollar.

 

 

 

 

h)

Share issuance costs

 

 

 

 

 

Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued.

 

 

 

 

i)

Research and development costs

 

 

 

 

 

Research and development costs are expensed as incurred.

 

 

 

 

j)

Revenue Recognition

 

 

 

 

 

The Company’s revenue is comprised of sales of cannabis products.

 

 

 

 

 

The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized.

 

 

 

 

 

Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.

 

 

 

 

 

For the three months ended November 30, 2020, the Company generated sales of $4,200.

 

 

 

 

k)

Net income (loss) per common share

 

 

 

 

 

Net income (loss) per share is calculated in accordance with ASC 260, Earnings per Share. The weighted-average number of common shares outstanding during each period is used to compute basic earning or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding to the extent the effect would not be antidilutive. Dilutive potential common shares are additional common shares assumed to be exercised.

 

 

 

 

 

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding.

 

 

 

 

l)

Income taxes

 

 

 

 

 

The Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

 
12

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

2.

Significant accounting  policies (continued)

 

 

 

 

m)

Related party transactions

 

 

 

 

 

Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts.

 

 

 

 

n)

Significant accounting estimates and judgments

 

 

 

 

 

The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates.

 

 

 

 

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

 

 

 

 

 

Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company’s ability to continue to as going concern as described in Note 1.

 

 

 

 

o)

Financial instruments

 

 

 

 

 

ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 825 prioritizes the inputs into three levels that may be used to measure fair value:

 

 

 

 

 

Level 1

 

 

 

 

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

 

 

 

 

Level 2

 

 

 

 

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

 

 

 

 

Level 3

 

 

 

 

 

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

 

 

 

 

The financial instruments consist principally of cash, due from related parties, accounts payable, note payable, convertible notes payable, and a loan payable to Allied. The fair value of cash when applicable is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of all other financial instruments which are categorized as loans and receivables approximate their current fair values because of their nature and respective relatively short maturity dates or current market rates of interest for similar instruments.

 

 
13

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

2.

Significant accounting  policies (continued)

 

 

 

 

 

For certain of the Company’s financial instruments, including accounts payable, due from related parties, notes and loans payable, the carrying amounts approximate their fair values due to the short maturities.

 

 

 

 

 

The Company does not have any assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet as of November 30, 2020 and August 31, 2020 other than cash.

 

 

 

 

 

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions.

 

 

 

 

p)

Leases

 

 

 

 

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. The Company adopted ASU 2016-02 on September 1, 2019, using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The Company did not have any leases until the acquisition of its wholly owned subsidiary, Allied Colombia S.A.S. on February 18, 2020.

 

 

 

 

 

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. The Company uses the implicit interest rate in the lease when readily determinable.

 

 

 

 

 

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7 – Leases.

 

 

 

 

q)

Reclassification

 

 

 

 

 

Certain reclassifications have been made to conform the prior period’s consolidated financial statements and notes to the current period’s presentation.

 

 

 

 

r)

Recent accounting pronouncements

 

 

 

 

 

The Company does not expect that recent accounting pronouncements or changes in accounting pronouncements during the three months ended November 30, 2020, are of significance or potential significance to the Company.

 

 
14

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

3.

Reverse acquisition transaction

 

 

 

 

Pursuant to the Reorganization Agreement (see Note 1(b)), effective on September 10, 2019, the Company acquired 100% of the issued and outstanding equity of AM Biosciences (the “Acquisition”). As consideration for the equity of AM Biosciences, the Allied Shareholder issued and delivered 51,200,014 shares of common stock, representing approximately 62.12% of the outstanding equity of the Company to SECFAC Exchange Corp. on behalf of the previous shareholders of AM Biosciences and other designees of AM Biosciences.

 

 

 

 

The Acquisition, was accounted for as a reverse asset acquisition pursuant to Topic 805, Business Combinations, as substantially all of the fair value of the assets acquired were concentrated in a group of similar non-financial assets, and the acquired assets did not have outputs or employees.

 

 

 

4.

Deposits and advances

 

 

 

November 30,

2020

 

 

August 31,

2020

 

a) Towards the purchase of prefabricated buildings

 

$ 2,585,540

 

 

$ 2,600,720

 

b) Refundable deposits towards future land acquisitions

 

 

-

 

 

 

174,030

 

c)  Vitalis equipment deposit

 

 

233,496

 

 

 

233,496

 

d) Other

 

 

17,936

 

 

 

-

 

Total deposits and advances

 

$ 2,836,972

 

 

$ 3,008,246

 

 

 

a)

In 2019, the Company entered to a separate modular building purchase agreement to acquire and construct an 8,700 square foot facility to be used as a certified cannabis cultivation and extraction facility. At November 30, 2020, Company had deposits of $2,585,540 (August 31, 2020 - $2,600,720) to purchase prefabricated buildings. As of November 30, 2020, the Company had not yet received the buildings and the amounts have been recorded as deposits.

 

 

 

 

b)

At November 30, 2020, the Company has entered into two purchase and sale agreements to acquire land as described in note 14(a).  At November 30, 2020, Company had deposits totaling $Nil (August 31, 2020 - $174,030). During the three months ended November 30, 2020, the Company received refund on deposits totaled $129,897.

 

 

 

 

c)

At November 30, 2020 and August 31, 2020, the Company had deposit of $233,496 to purchase equipment as described in Note 14(b). At November 30, 2020, the Company had not yet received the equipment and the amount paid has been recorded as a deposit.

 

 
15

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

5.

Property, plant and equipment

 

 

 

At November 30, 2020, property, plant and equipment consisted of:

 

 

 

Construction

in process

 

 

Machinery

and

equipment

 

 

Office and computer equipment

 

 

Land

equipment

 

 

Total

 

Cost

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

August 31, 2020

 

$ 136,114

 

 

$ 79,956

 

 

$ 3,161

 

 

$ 6,000

 

 

$ 225,231

 

Additions

 

 

10,924

 

 

 

3,475

 

 

 

7,533

 

 

 

-

 

 

 

21,932

 

Foreign exchange

 

 

4,718

 

 

 

2,663

 

 

 

377

 

 

 

190

 

 

 

7,948

 

November 30, 2020

 

$ 151,756

 

 

$ 86,094

 

 

$ 11,071

 

 

$ 6,190

 

 

$ 255,111

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated depreciation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

August 31, 2020

 

$ -

 

 

$ 2,211

 

 

$ -

 

 

$ -

 

 

$ 2,211

 

Additions

 

 

-

 

 

 

3,860

 

 

 

960

 

 

 

350

 

 

 

5,170

 

Foreign exchange

 

 

-

 

 

 

693

 

 

 

36

 

 

 

13

 

 

 

644

 

November 30, 2020

 

$ -

 

 

$ 5,378

 

 

$ 996

 

 

$ 363

 

 

$ 6,737

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net book value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

August 31, 2020

 

$ 136,114

 

 

$ 77,745

 

 

$ 3,161

 

 

$ 6,000

 

 

$ 223,020

 

November 30, 2020

 

$ 151,756

 

 

$ 80,716

 

 

$ 10,075

 

 

$ 5,827

 

 

$ 248,374

 

 

 

As of November 30, 2020, the construction in process has not been use. For the quarter ended November 30, 2020, no amortization has been recorded.

 

 
16

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

6.

Intangible assets

 

 

 

At November 30, 2020, intangible assets consisted of:

 

 

 

Cost

$

 

 

Foreign exchange

$

 

 

Accumulated amortization

$

 

 

Impairment

$

 

 

November 30, 2020

Net carrying value

$

 

 

August 31, 2020

Net carrying value

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cannabis licenses

 

 

5,435,334

 

 

 

(416,739 )

 

 

(624,790 )

 

 

(1,113,972 )

 

 

3,279,833

 

 

 

3,300,000

 

 

 

 

5,435,334

 

 

 

(416,739 )

 

 

(624,790 )

 

 

(1,113,972 )

 

 

3,279,833

 

 

 

3,300,000

 

 

 

On February 17, 2020, the Company acquired $5,435,334 of licenses as part of the acquisition of Medicolumbia. The licenses acquired are issued by the Republic of Colombia and include the use of seeds for growing Cannabis, production of derivatives from Cannabis for medicinal and scientific use, cultivation of Cannabis plants, and producer of seeds. The Company has recorded amortization of these licenses of $160,932 for the quarter ended November 30, 2020.

 

 

7.

Leases

 

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. The Company also elected to keep all leases with an initial term of 12 months or less off the balance sheet.

 

 

 

The Company did not have any leases until the acquisition of Medicolombia during the year ended August 31, 2020. The acquisition resulted in the addition of $82,398 of operating lease assets and liabilities.

 

 

 

The Company entered into an agreement to lease the land described in Note 4(b) and 14(a) with a commencement date of June 1, 2020. The lease requires the Company to make monthly payments of $4,501 (CAD$5,870) per month.  The lease is for a 10-year term, expiring on May 31, 2030, with one 10-year renewal option and an option for the Company to purchase the land for approximately $920,000 (CAD$1,200,000).  Effective November 1, 2020, the Company terminated the lease. Pursuant to ASC 842-20 upon the termination of the lease, the Company derecognized the lease related asset and liability and included any consideration paid or received upon termination that was not already included in the lease payments in the gain or loss on termination of the lease.  After recording the proceeds from the landlord and derecognizing the capitalized building costs as well as the right of use asset and liability, the Company recorded a loss of $65,565 on the termination of the lease.

 

 

 

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate.  Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is amortized over the lease term.  For operating leases, interest on the lease liability and the amortization of the ROU asset result in straight-line rent expense over the lease term.  For finance leases, interest on the lease liability and the amortization of the ROU asset results in front-loaded expense over the lease term.  ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. At November 30, 2020, the Company did not have any finance leases.

 

 

 

At November 30, 2020, the weighted average remaining operating lease term was 9.25 years and the weighted average discount rate associated with operating leases was 15%.

 

 
17

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

7.

Leases (continued)

 

 

 

The Components of lease expenses were as follows:

 

 

 

$

 

Operating lease cost:

 

 

 

Amortization of right-of-use assets

 

 

3,578

 

Interest on lease liabilities

 

 

9,543

 

 

 

 

 

 

Total operating lease cost

 

 

13,121

 

 

 

The following table provides supplemental cash flow and other information related to leases for the three months ended November 30, 2020:

 

 

 

$

 

Lease payments

 

 

12,480

 

 

 

Supplemental balance sheet information related to leases as of November 30, 2020 are as below:

 

 

 

$

 

Cost

 

 

387,573

 

Accumulated amortization

 

 

(8,595 )

Lease termination

 

 

(299,089 )

Foreign exchange

 

 

(5,270 )

 

 

 

 

 

Net carrying value at November 30, 2020

 

 

74,619

 

 

 

Future minimum lease payments related to lease obligations are as follows:

 

 

 

$

 

2021

 

 

11,174

 

2022

 

 

14,899

 

2023

 

 

14,899

 

2024

 

 

14,899

 

Thereafter

 

 

83,185

 

 

 

 

 

 

Total minimum lease payments

 

 

139,056

 

 

 

 

 

 

Less: amount of lease payments representing effects of discounting

 

 

(64,437 )

 

 

 

 

 

Present value of future minimum lease payments

 

 

74,619

 

 

 

 

 

 

Less: current obligations under leases

 

 

(3,972 )

 

 

 

 

 

Lease liabilities, net of current portion

 

 

70,647

 

 

8.

Loan Payable

 

 

 

In June 2020, the Company entered into a financing agreement to finance the buildings described in Note 4(a). Pursuant to the agreement, the Company financed $1,253,772 of the purchase price. The Company paid $71,023 at commencement date on May 29, 2020, and will make six monthly interest payments of $37,613 commencing June 20, 2020 and repay the principal of $1,253,772 on November 20, 2020. During the three months ended November 30, 2020, the Company amended the loan agreement to extend the repayment due date to May 20, 2021. During the three months ended November 30, 2020, the Company paid interest in the amount of $112,840.

 

 
18

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

9.

Convertible Notes

 

 

 

 

 

a)

On January 23, 2020, the Company issued two convertible notes with principal amounts of $400,000 and $200,000, respectively, with a total face value of $600,000 (the “Notes”) and warrants to purchase 240,000 shares of the Company’s common stock at $1.25 per share for 1 year. The Notes were issued with an original discount of $12,000, and bear interest at 10% per annum compounded monthly. The notes were to mature on July 20, 2020 and convertible into shares of the Company’s common stock at any time prior to maturity at a conversion price of $1.25 per share.

 

 

 

 

 

The Company evaluated whether separate financial instruments with the same terms as the conversion features above would meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25. The Company determined that there was no derivative liability associated with the debenture or warrants under ASC 815-15 Derivatives and Hedging. The terms of the contracts do not permit net settlement, as the shares delivered upon conversion are not readily convertible to cash. The Company’s trading history indicated that the shares are thinly traded and the market would not absorb the sale of the shares issued upon conversion without significantly affecting the price. As the conversion features would not meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25, the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, the conversion features and warrants would not meet derivative classification.

 

 

 

 

 

The relative fair values of the convertible note and the warrants were $470,467 and $117,533 respectively. The effective conversion price was then determined to be $0.98. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $115,383 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $108,100 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $364,517. The beneficial conversion feature of $115,383, the original issue discount of $12,000 and the relative fair value of the warrants of $108,100 discounted the carrying value of the convertible debt on the date of issue. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. On June 30, 2020, the Company repaid $200,000 of the $600,000 note which left $400,000 outstanding on each note.

 

 

 

 

 

i.

First Modification:

 

 

 

 

 

 

 

On July 1, 2020, the Company entered into amendments to the convertible notes. Pursuant to the amendments, beginning on July 1, 2020, the convertible notes bear simple interest at 5% per annum. The maturity date of the convertible notes was amended to due on demand on or before October 31, 2020. In consideration for extending the maturity date, the Company issued to the convertible note holders 16,000 common shares of the Company and warrants to purchase additional 320,000 common shares of the Company at $1.25 per share expiring October 31, 2021. Each note holder received 8,000 common shares and 160,000 warrants.

 

 

 

 

 

 

 

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-60 was applied. As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was substantially different which resulted in extinguishment accounting.

 

 
19

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

9.

Convertible Notes (continued)

 

 

 

 

 

 

 

The extended convertible notes had a total carrying value of $400,000. As the common shares and warrants were issued as consideration for extending the convertible notes, the fair value of the common share and warrants of $218,397 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $220,065.

 

 

 

 

 

 

ii.

Second Modification:

 

 

 

 

 

 

 

On November 1, 2020, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or before March 31, 2021. In consideration for extending the maturity date, the Company agreed to issue to the convertible note holders 100,000 common shares of the Company. Each note holder will receive 50,000 common shares.

 

 

 

 

 

 

 

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-60 was applied. As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was substantially different which resulted in extinguishment accounting.

 

 

 

 

 

 

 

The extended convertible notes had a total carrying value of $400,000. As the common shares were issued as consideration for extending the convertible notes, the fair value of the common share of $110,00 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $110,000 and as the common shares had not been issued as of November 30, 2020 and have been recorded as common shares issuable.

 

 

 

 

 

 

 

As at November 30, 2020, the Company has recorded accrued interest of $26,290, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

 

 

 

 

 

b)

On September 29, 2020, the Company issued a convertible note with a fair value of $163,341 (the “Note 1”) and warrants to purchase 130,673 shares of the Company’s common stock at $1.25 per share for 2 years.   The Note 1 bears interest at 10% per annum. The Note 1 is due on demand after March 27, 2021.  The Note 1 is convertible into shares of the Company’s common stock at any time prior to March 27, 2021 at a conversion price of $1.25 per share.  

 

 

 

 

 

 

The Company has evaluated whether separate financial instruments with the same terms as the conversion features above would meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25. The Company determined that there was no derivative liability associated with the debenture or warrants under ASC 815-15 Derivatives and Hedging. The terms of the contracts do not permit net settlement, as the shares delivered upon conversion are not readily convertible to cash. The Company’s trading history indicated that the shares are thinly traded and the market would not absorb the sale of the shares issued upon conversion without significantly affecting the price. As the conversion features would not meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25, the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2020, the conversion features and warrants do not meet derivative classification.

 

 
20

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

9.

Convertible Notes (continued)

 

 

 

 

 

The relative fair values of the convertible note and the warrants were $85,330 and $78,011 respectively. The effective conversion price was then determined to be $0.65. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $85,330 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $78,011 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil at issuance. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

 

 

 

 

 

As at November 30, 2020, the Company has recorded accrued interest of $2,775, which is included in accounts payable and accrued liabilities on the consolidated balance sheets. During the three months ended November 30, 2020, the Company recognized accretion of $37,046 on the Note 1.

 

 

 

 

c)

On October 26, 2020, the Company issued a convertible note with a face value of $37,613 (the “Note 2”) and warrants to purchase 30,090 shares of the Company’s common stock at $1.25 per share for 2 years.   The Note bears interest at 10% per annum. The Note is due on demand after April 23, 2021.  The Note is convertible into shares of the Company’s common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share. 

 

 

 

 

 

The Company has evaluated whether separate financial instruments with the same terms as the conversion features above would meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25. The Company determined that there was no derivative liability associated with the debenture or warrants under ASC 815-15 Derivatives and Hedging. The terms of the contracts do not permit net settlement, as the shares delivered upon conversion are not readily convertible to cash. The Company’s trading history indicated that the shares are thinly traded and the market would not absorb the sale of the shares issued upon conversion without significantly affecting the price. As the conversion features would not meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25, the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2020, the conversion features and warrants do not meet derivative classification.

 

 

 

 

 

The relative fair values of the convertible note and the warrants were $20,176 and $17,437 respectively. The effective conversion price was then determined to be $0.65. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $20,176 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $17,437 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

 

 

 

 

 

As at November 30, 2020, the Company has recorded accrued interest of $361, which is included in accounts payable and accrued liabilities on the consolidated balance sheets. During the three months ended November 30, 2020, the Company recognized accretion of $6,411 on the Note 2.

 

 

 

 

d)

On November 11, 2020, the Company issued a convertible note with a face value of $85,937 (the “Note 3”) and warrants to purchase 68,750 shares of the Company’s common stock at $1.25 per share for 2 years.   The Note bears interest at 10% per annum. The Note is due on demand after May 9, 2021.  The Note is convertible into shares of the Company’s common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share.    

 

 
21

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

9.

Convertible Notes (continued)

 

 

 

The Company has evaluated whether separate financial instruments with the same terms as the conversion features above would meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25. The Company determined that there was no derivative liability associated with the debenture or warrants under ASC 815-15 Derivatives and Hedging. The terms of the contracts do not permit net settlement, as the shares delivered upon conversion are not readily convertible to cash. The Company’s trading history indicated that the shares are thinly traded and the market would not absorb the sale of the shares issued upon conversion without significantly affecting the price. As the conversion features would not meet the characteristics of a derivative instrument as described in paragraphs ASC 815-15-25, the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2020, the conversion features and warrants do not meet derivative classification.

 

 

 

The relative fair values of the convertible note and the warrants were $48,258 and $37,679 respectively. The effective conversion price was then determined to be $0.70. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $48,258 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $37,679 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

 

 

 

As at November 30, 2020, the Company has recorded accrued interest of $447, which is included in accounts payable and accrued liabilities on the consolidated balance sheets. During the three months ended November 30, 2020, the Company recognized accretion of $12,026 on the Note 3.

 

 
22

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

10.

Equity

 

 

 

During the three months ended November 30, 2019

 

 

 

Pursuant to the Acquisition described in Note 1, the Allied Shareholder submitted for cancellation and return to treasury 10,459,220 shares of common stock.

 

 

 

During the three months ended November 30, 2020

 

 

 

On September 30, 2020, the Company issued 120,000 shares of common stock at $1.25 per share for gross cash proceeds of $150,000.

 

 

 

In connection with the extension of convertible notes payable, as of November 30, 2020, the Company has common stock issuable of $129,952 (August 31, 2020 - $19,952).

 

 

11.

Related party transactions and balances

 

 

 

All transactions with related parties have occurred in the normal course of operations and are recorded at the exchange amount which is the amount agreed to by the Company and the related party.

 

 

 

 

a)

Key management compensation and related party transactions

 

 

 

 

 

The Company has identified its directors and certain senior officers as its key management personnel. The compensation costs for key management personnel for the three months ended November 30, 2020 and 2019 were as follows:

 

 

 

November 30,

2020

 

 

November 30,

2019

 

Consulting fees and benefits

 

$ 88,865

 

 

$ 216,041

 

 

 

b)

Amounts due to/from related parties

 

 

 

 

 

In the normal course of operations, the company shares certain administrative resources with companies related by common management and directors. The administrative resources and services, which were provided in the normal course of operations, were measured at the exchange. All amounts payable and receivable are non-interest bearing, unsecured and due on demand. The following table summarizes the amounts were due to related parties:

 

 

 

November 30,

2020

 

 

August 31,

2020

 

CEO and Director

 

$ (12,372 )

 

$ (12,588 )

COO and Director

 

 

(40,912 )

 

 

(42,059 )

1176149 B.C. Ltd.  – an entity controlled by the CFO

 

 

(29,667 )

 

 

(10,797 )

Edjudicate LLC – an entity controlled by a director

 

 

(15,000 )

 

 

(5,142 )

 

 

$ (97,951 )

 

$ (70,586 )

 

 

 

As of August 31, 2020, the Company advanced $23,517 to related parties for future expenses, which was included in prepaid expenses on the consolidated balance sheets. As of November 30 2020, the Company had $97,951 (August 31, 2020 - $70,586) payable to related parties for expenses incurred or expensed paid on behalf of the Company by the parties which has been presented in accounts payable and accrued liabilities.

 

 
23

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

12.

Financial risk factors

 

 

 

 

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

 

 

 

 

a)

Credit risk:

 

 

 

 

 

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company’s primary exposure to credit risk is on its cash account. Cash accounts are held with major banks in Canada. The Company has deposited its cash with a bank from which management believes the risk of loss is low.

 

 

 

 

b)

Liquidity risk:

 

 

 

 

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company’s approach to managing liquidity is to ensure that it will have sufficient liquidity to meet liabilities when due. Accounts payable are due within the current operating period. The Company has a working capital deficit and requires additional financing to meet its current obligations (see Note 1).

 

 

 

 

c)

Market risk:

 

 

 

 

 

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company’s income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. The Company is not exposed to market risk.

 

 

 

 

d)

Interest rate risk:

 

 

 

 

 

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk, from time to time, on its cash balances. Surplus cash, if any, is placed on call with financial institutions and management actively negotiates favorable market related interest rates.

 

 
24

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

12.

Financial  risk factors (continued)

 

 

 

 

e)

Foreign exchange risk:

 

 

 

 

 

Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the Canadian dollar. The Company has not entered into any foreign currency contracts to mitigate risk, but manages the risk my minimizing the value of financial instruments denominated in foreign currency. The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Canadian dollars:

 

 

 

November 30,

2020

 

Balance in Canadian dollars:

 

 

 

Cash and cash equivalents

 

$ -

 

Accounts payable

 

 

(458,040 )

Net exposure

 

 

(458,040 )

Balance in US dollars:

 

$ (352,963 )

 

 

 

A 10% change in the US dollar to the Canadian dollar exchange rate would impact the Company’s net loss by approximately $35,296 for the three months ended November 30, 2020 (November 30, 2019 – $16,226).

 

 

 

 

 

The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Colombian Pesos:

 

 

 

November 30,

2020

 

Balance in Colombian Pesos dollars:

 

 

 

Cash and cash equivalents

 

$ 19,756,915

 

Accounts payable

 

 

(2,716,625,191 )

Net exposure

 

 

(2,696,868,275 )

Balance in US dollars:

 

$ (744,081 )

 

 

 

A 10% change in the US dollar to the Colombian Peso exchange rate would impact the Company’s net loss by approximately $74,408 for the three months ended November 30, 2020.

 

 

 

13.

Capital management

 

 

 

 

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the business and continue as a going concern. The Company considers capital to be all accounts in equity. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company’s management to sustain future development of the business. The Company has a working capital deficit and requires additional capital to finance is future business plans. The Company is not subject to any externally imposed capital requirements.

 

 

 

14.

Commitments and contingencies

 

 

 

 

a)

On November 6, 2018, the Company signed an assignment to purchase two separate lots located at 8999 Jim Bailey Road in Kelowna, British Columbia, Canada. The land is zoned I2 General Industrial and allow for “Cannabis Production Facilities” as a principal use.

 

 
25

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

14.

Commitments and contingencies (continued)

 

 

 

 

The total commitment for the two parcels of land are CAD$1,942,250 (US$1,457,367) (Lot 1 - $988,550, Lot 2 - CAD$953,700). During the year ended August 31, 2019, the Company executed several “offer to purchase amendments” to defer the assignment and close of the two parcels of land. On November 11, 2019, the Company executed an additional offer to purchase amendment to extend the assignment and close of the land parcels no later than February 10, 2020 and there was an additional amendment to extend the close of the purchase to May 2020. On May 7, 2020, the Company assigned the purchase of Lot 1 to a third party. In June 2020, the Company entered into a lease agreement to lease Lot 1 from the third party for an annual rent of CAD$70,442 for 10 years commencing June 1, 2020 until May 31, 2030, on November 1, 2020 the lease agreement was terminated.

 

 

 

 

 

In November 2019, the board of directors determined the Company would not close on Lot 2 as the parcel of land will not be required for future operations. As a result, the Company does not have a commitment to pay the value of CAD$953,700 for the land and will eligible to receive or assign the initial refundable deposit of CAD$10,000. During the year ended August 31, 2020, this contract of purchase and sale for LOT 2 – 8999 Jim Bailey Road was assigned to another non related party.

 

 

 

 

b)

On August 30, 2019, the Company entered into sales agreement to purchase an extraction system to be use in future at its operation in Colombia. The equipment has a value of CAD$658,260. The terms of the agreement require the Company to pay the full amount in monthly installments starting September 1, 2019 and will continue to February 2020. The equipment will be paid in full before the equipment is shipped to Colombia and title transfers to the Company. At November 30, 2020, the $233,496 has been recorded as a deposit until the remaining purchase price is paid and the equipment is received.

 

 

 

 

c)

As of November 30, 2020, the Company recorded a contingent liability of $536,727 for expenses in connection with MediColombia, which is included in the balance of accounts payable and accrued liabilities on the unaudited condensed consolidated balance sheets.

 

 

 

 

d)

In September 2020, the Company entered into settlement and release agreements to settle claims with former directors and officers of the Company whereby the Company will make aggregate payments of $105,000, which is included in the balance of accounts payable and accrued liabilities on the unaudited condensed consolidated balance sheets.

 

 
26

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

15.

Share purchase warrants

 

 

 

 

The following table summarizes the continuity of share purchase warrants:

 

 

 

Number of

warrants

 

 

Weighted

average

exercise price

$

 

 

 

 

 

 

 

 

Balance, August 31, 2020

 

 

560,000

 

 

 

1.25

 

Issued

 

 

229,513

 

 

 

1.25

 

Balance, November 30, 2020

 

 

789,513

 

 

 

1.25

 

 

            As at November 30, 2020, the following share purchase warrants were outstanding:

 

Number of warrants

 

 

Exercise

price

$

 

 

Expiry date

 

 

 

 

 

 

 

 

 

 

240,000

 

 

 

1.25

 

 

January 23, 2021

 

 

320,000

 

 

 

1.25

 

 

October 31 2021

 

 

130,673

 

 

 

1.25

 

 

September 29, 2022

 

 

30,090

 

 

 

1.25

 

 

October 16, 2022

 

 

68,750

 

 

 

1.25

 

 

November 11, 2022

 

 

16.

Non-cash activities

 

 

 

For the Three

Months

Ended

November 30,

2020

 

 

For the Three

Months

Ended

November 30,

2019

 

Non-cash activities:

 

 

 

 

 

 

Beneficial conversion feature

 

 

153,764

 

 

 

-

 

Relative fair value of warrants issuable with convertible notes

 

 

133,127

 

 

 

-

 

Relative fair value of shares issued on modification of convertible notes

 

 

110,000

 

 

 

-

 

 

 
27

Table of Contents

 

ALLIED CORP.

Notes to the Condensed Consolidated Interim Financial Statements

November 30, 2020

(Expressed in US dollars)

 

17.

Segment disclosure

 

 

 

During the three months ended November 30, 2019 and as of November 30, 2019, the Company had only one operating segment.

 

 

 

During the three months ended November 30, 2020, and as of November 30, 2020, the Company had two operating segments including:

 

 

 

 

a)

Allied Columbia SAS, a Columbian based company through which the Company intends to commence commercial production in Colombia. (Medicolombias)

 

 

 

 

b)

Allied Corp. which consists of the rest of the Company’s operations. (Allied)

 

 

 

 

Factors used to identify the Company’s reportable segments include the organizational structure of the Company and the financial information available for evaluation by the chief operating decision-maker in making decisions about how to allocate resources and assess performance. The Company’s operating segments have been broken out based on similar economic and other qualitative criteria. The Company operates the Allied reporting segment in one geographical area (Canada), and the Medicolombia reporting segment in one geographical area (Colombia).

 

 

 

Financial statement information by operating segment for the three months ended November 30, 2020 is presented below:

 

 

 

Allied

$

 

 

Medicolombia

$

 

 

Total

$

 

Net sales

 

 

4,200

 

 

 

-

 

 

 

4,200

 

Net loss

 

 

(868,999 )

 

 

(326,863 )

 

 

(1,195,862 )

Accretion

 

 

55,483

 

 

 

-

 

 

 

55,483

 

Depreciation and amortization

 

 

-

 

 

 

169,680

 

 

 

169,680

 

Total Assets as of November 30, 2020

 

 

2,822,749

 

 

 

3,710,416

 

 

 

6,533,165

 

 

Geographic information for the three months ended and as at November 30, 2020 is presented below:

 

 

 

Revenues

$

 

 

Total

Assets

$

 

 

 

 

 

 

 

 

Canada

 

 

4,200

 

 

 

2,822,749

 

Colombia

 

 

-

 

 

 

3,710,416

 

Total

 

 

4,200

 

 

 

6,533,165

 

 

18.

Subsequent event

 

 

 

Subsequent to November 30, 2020, the Company entered into agreements to issue $900,000 of convertible notes. To date, the Company has received gross proceeds of $800,000. The convertible notes are due one year from the issuance date and bear interest at 10% per annum. The notes are convertible into common shares of the Company at a conversion price of $1.25 per share.

  

 
28

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion relates to the historical operations and financial statements of Allied Corp. for the three months ended November 30, 2019 and 2020.

 

Forward-Looking Statements

 

The following Management’s Discussion and Analysis should be read in conjunction with our financial statements and the related notes thereto included elsewhere in this Annual Report. The Management’s Discussion and Analysis contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect,” and the like, and/or future-tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in this Annual Report. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading “Risks Factors” in our various filings with the Securities and Exchange Commission. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report.

 

As a result of the Reorganization Agreement and the change in business and operations of the Company, a discussion of the past financial results of the Company, formally known as Cosmo Ventures, Inc., is not pertinent, and, under generally accepted accounting principles in the United States the historical financial results of AM Biosciences, the acquirer for accounting purposes, prior to the Reorganization Agreement are considered the historical financial results of the Company.

 

The following discussion highlights the Company’s results of operations and the principal factors that have affected its consolidated financial condition as well as its liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the Company’s consolidated financial condition and results of operations presented herein. The following discussion and analysis are based Allied Corp’s audited and unaudited financial statements contained in this Current Report, which have been prepared in accordance with generally accepted accounting principles in the United States. You should read the discussion and analysis together with such financial statements and the related notes thereto.

 

Overview

 

Allied (or “Allied” or the Company) is a public Nevada corporation focused on bringing to market medical cannabis in Canada initially, via our wholly-owned subsidiary AM (Advanced Micro) Biosciences, Inc. that has end stage national license applications.

 

Allied has expanded internationally into South America via acquisitions of national license holders. As a research and development company, Allied’s focus is on creating and providing targeted cannabinoid health solutions for today’s medical issues. One of our top R&D priorities is developing effective Post Traumatic Stress Disorder (PTSD)/Post Traumatic Stress Injury (PTSI) solutions.

 

Led by a team of experienced Industry experts, Allied will use that valuable data to properly select and secure the appropriate products and business activities to ensure the company’s success.

 

The Company’s vertically integrated approach focuses on sufferers of PTSD. This market includes:

 

·

Canadian Veterans, with initially an approximate 6,000 veterans available for first contact and onboarding, and a veteran base of approximately 650,000 in Canada from the War Service and Canadian Armed Forces

 

 
29

Table of Contents

 

·

An additional 2,000,000+ Canadian veterans who also suffer in certain numbers from PTSD, including estimates of:

 

 

 

·

740,000 RCMP/Police Officers

 

 

 

·

925,000 Correctional Services Canada/Canadian Border Services Agency/Canadian Peace Officers

 

 

 

·

280,000 Firefighters (not including volunteers)

 

 

 

·

75,000 Paramedics

 

 

 

·

Potential South American market

 

 

 

·

Potential United States market: approximately 15 million veterans.

 

The Company’s additional focus is on neutraceutical products for veterans and general public through bringing hemp derived nano-technology products to market in the United States. Differentiators from our competitors potentially include the low cost, high margin production that Allied has available via Colombian Production.

 

Critical Accounting Policies

 

Basis of presentation

 

These unaudited condensed consolidated interim financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and are expressed in United States dollars. The Company’s fiscal year end is August 31.

 

These unaudited condensed consolidated interim financial statements have been prepared in accordance with US GAAP for interim financial information and with the instructions to Securities and Exchange Commission (“SEC”) Form 10-Q. They do not include all of the information and footnotes required by US GAAP to complete financial statements. Therefore, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended August 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC.

 

The unaudited condensed consolidated interim financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at November 30, 2020, and the results of its operations for the three months ended November 30, 2020 and cash flows for the three months ended November 30, 2020. The results of operations for the period ended November 30, 2020 are not necessarily indicative of the results to be expected for future quarters or the full year.

 

The significant accounting policies followed are:

 

a. Principles of consolidation

 

The unaudited condensed consolidated interim financial statements include accounts of Allied Corp. and its subsidiaries. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.

 

b. Cash and cash equivalents

 

Cash is comprised of cash on hand, cash held in trust accounts and demand deposits. Cash equivalents are short-term, highly liquid investments with maturities within nine months when acquired. The Company did not have any cash equivalents as of November 30, 2020 and August 31, 2020.

 

 
30

Table of Contents

 

c. Property and Equipment

 

Property and equipment are stated at cost. The Company depreciates the cost of property and equipment over their estimated useful lives at the following annual rates:

 

Equipment

10 years straight-line basis

Office and computer equipment

5 years straight-line basis

Agricultural equipment

10 years straight-line basis

 

d. Inventory

 

Inventories are stated at the lower of cost or market. As of November 30, 2020 and August 31, 2020, the inventory consisted of supplies of containers and packaging.

 

e. Intangible assets

 

At November 30, 2020 and August 31, 2020, intangible assets include licenses which are being amortized over their estimated useful lives of 3-10 years. The Company’s licenses are amortized over their economic or legal life on a straight-line basis, whichever is shorter. The licenses have been amortized from the date of acquisition.

 

The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives.

 

For long-lived assets, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

 

f. Long-lived assets

  

In accordance with ASC 360, Property, Plant and Equipment, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

 

g. Foreign currency translation and functional currency conversion

 

Items included in these unaudited condensed consolidated interim financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entities operate (the “functional currency”).

 

Prior to September 10, 2019, the Company’s functional currency was the Canadian dollar. Translation gains and losses from the application of the U.S. dollar as the reporting currency during the period that the Canadian dollar was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss.

 

The Company re-assessed its functional currency and determined as at September 10, 2019, its functional currency changed from the Canadian dollar to the U.S. dollar based on management’s analysis of changes in our organization including the RTO. The change in functional currency was accounted for prospectively from September 10, 2019 and financial statements prior were not restated for the change in functional currency.

 

 
31

Table of Contents

 

For periods commencing September 10, 2019, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets and non-monetary liabilities incurred after September 10, 2019 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transaction. Foreign exchange gains and losses are included in the statement of operations and comprehensive loss as foreign exchange gains.

 

The Company assessed the functional currency for Allied Columbia S.A.S. (previously MediColombia), a wholly owned subsidiary acquired by the Company on February 18, 2020 to be Colombian peso.

 

The functional currency for Tactical Relief LLC is U.S. dollar.

 

h. Share issuance costs

 

Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued.

 

i. Revenue recognition

 

The Company’s revenue is comprised of sales of cannabis products

 

The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized.

 

Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.

 

j. Research and development costs

 

Research and development costs are expensed as incurred.

 

k. Net income (loss) per common share

 

Net income (loss) per share is calculated in accordance with ASC 260, “Earnings per Share.” The weighted-average number of common shares outstanding during each period is used to compute basic earning or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding to the extent the effect would not be antidilutive. Dilutive potential common shares are additional common shares assumed to be exercised.

 

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding.

 

 
32

Table of Contents

 

l. Income taxes

 

The Company accounts for income taxes under ASC 740 “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

m. Related party transactions

 

Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts.

 

n. Significant accounting estimates and judgments

 

The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

 

Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company’s ability to continue to as going concern.

 

o. Financial instruments

 

ASC 825, “Financial Instruments,” requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 825 prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

 
33

Table of Contents

 

Level 3

 

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

The financial instruments consist principally of cash, accounts receivable, due from related parties, accounts payable, note payable, loan payable to Allied, due to related party and convertible note payable. The fair value of cash when applicable is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of all other financial instruments which are categorized as loans and receivables approximate their current fair values because of their nature and respective relatively short maturity dates or current market rates of interest for similar instruments.

 

p. Leases

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. The Company adopted ASU 2016-02 on September 1, 2019, using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The Company did not have any leases until the acquisition of its wholly owned subsidiary, Allied Colombia S.A.S. on February 18, 2020.

 

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. The Company uses the implicit interest rate in the lease when readily determinable.

 

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability.

 

q. Reclassification

 

Certain reclassifications have been made to conform the prior period’s consolidated financial statements and notes to the current year’s presentation.

 

r. Recent accounting pronouncements

 

The Company does not expect that recent accounting pronouncements or changes in accounting pronouncements during the three months ended November 30, 2020, are of significance or potential significance to the Company.

 

Financial Condition and Results of Operations

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company incurred a net loss for the three months ended November 30, 2020 of $1,195,862 and has minimal operations at this time which will generate revenue. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise sufficient financing to acquire or develop a profitable business. Management intends on financing its operations and future development activities largely from the sale of equity securities with some additional funding from other traditional financing sources, including related party loans until such time that funds provided by future planned operations are sufficient to fund working capital requirements.

 

 
34

Table of Contents

 

Results of Operations

 

Three Months Ended November 30, 2020

 

For the three month period ended November 30, 2020 we had $4,200 in revenue. We had no revenue for the three month period ended November 30, 2019. Operating expenses for the three month period ended November 30, 2020 totaled $864,014. Operating expenses for the nine-month period ended November 30, 2020 is mainly a result of office and general expense of $105,812, professional fees of $130,631 and consulting fees of $327,843. Operating expenses for the period ended November 30, 2019 totaled $458,167. Operating expenses for the period ended November 30, 2019 is mainly a result of office and general expense of $80,971, professional fees of $146,548 and consulting fees of $174,140. These expenses consisted principally of consulting fees in the development of the Company’s cannabis business, general office expenses, professional fees and rent. The overall increase in operating expenses during the three month period ended November 30, 2020 is the result of acquisitions, a change of business and an increase in business activities.

 

During the three month period ended November 30, 2020, the Company incurred additional expenses of $65,565 for termination of a lease, $110,000 on loss on extinguishment of an obligation, settlement payments with certain former directors and officers of $105,000, and recorded accretion of $55,483. The Company did not have comparable expenses during the period ended November 30, 2019.

 

As a result of the changes described above, net loss from operations after income taxes increased to $1,195,862 during the three months ended November 30, 2020 compared to $458,167 during the period ended November 30, 2019.

 

Liquidity and Capital Resources

 

As of November 30, 2020, the Company had $93,367 in current assets, consisting of $11,395 in cash, $60,486 in inventory, $21,486 in prepaid expenses. Other assets mainly include deposits and advances of $2,836,972, property plant and equipment of $248,374 and intangible assets of $3,279,833.

 

On September 21, 2020, the Company issued 80,000 shares to an accredited investor who purchased such shares in a private placement at a purchase price of $1.25 per share for gross cash proceeds of $100,000.

 

On September 30, 2020, the Company issued 120,000 shares to two accredited investors who purchased such shares in a private placement at a purchase price of $1.25 per share for gross cash proceeds of $150,000.

 

On September 29, 2020, the company issued a convertible note with a face value of $163,341 and warrants to purchase 130,673 shares of the company’s common stock at $1.25 per share for 2 years. The note is convertible at any time through the date which is 179 days from the date of issuance at a conversion price of $1.25 per share.

 

On October 9th, 2020 the Company, through AMBI, its wholly owned subsidiary, and Activated Nano signed and executed a termination agreement whereby Activated Nano agrees to return for cancellation 250,000 shares of Allied Corp., acknowledges and agrees that no further payments shall be made by AMBI with respect to the agreement and that Activate Nano may retain the $10,000 deposit pursuant to the original agreement.

 

On October 26, 2020, the company issued a convertible note with a face value of $37,613 and warrants to purchase 30,090 shares of the company’s common stock at $1.25 per share for 2 years. The note is convertible at any time through the date which is 179 days from the date of issuance at a conversion price of $1.25 per share.

 

 
35

Table of Contents

 

On November 11, 2020, the company issued a convertible note with a face value of $85,937 and warrants to purchase 68,750 shares of the company’s common stock at $1.25 per share for 2 years. The note is convertible at any time through the date which is 179 days from the date of issuance at a conversion price of $1.25 per share.

 

On November 20, 2020, the Company and the previous owner of Falcon Ridge reached mutual consent that the 950,000 common shares of Allied Corp. in connection with acquisition of Falcon Ridge will be returned to the Company and the Company will return all the common shares of Falcon Ridge to the previous owner.

 

On December 2, 2020, the company issued convertible notes to two accredited investors with a face value of $600,000 and warrants to purchase 240,000 shares of the company’s common stock at $1.25 per share for 2 years. The notes are convertible at any time through the date which is 365 days from the date of issuance at a conversion price of $1.25 per share.

 

In connection with its proposed business plan and currently ongoing and proposed acquisitions, the Company will be required to complete substantial and significant additional capital formation. Such formation could be through additional equity offerings, debt, bank financings or a combination of any source of financing. There can be no assurance that the Company will be successful in completion of such financings.

 

Capital Expenditures

 

As of November 30, 2020 the company had purchased property plant and equipment of $248,374 and paid net cash of $2,836,972 in deposits for an asset acquisition. As of August 31, 2020, the Company purchased property plant and equipment of $223,020 and paid net cash of $3,008,246 in deposits and advances for an asset acquisition.

 

 
36

Table of Contents

 

MediColombias Acquisition (Colombia Licensed Producer)

 

On August 29, 2019, the Company entered into a Share Purchase Agreement (“Purchase Agreement”) with Dorson Commercial Corp. (“Dorson”) as the sole owner of Baleno Ltd. to purchase all of the issued and outstanding shares of Baleno Ltd., the sole owner of Medicolombia Cannabis S.A.S. (“Medicolombia”). Medicolombia is based in Colombia with a full set of licenses and a lease agreement in place to begin production on a 5 hectare parcel of land. We have the ability to scale production to over hundreds of hectares. This is located in the area of Bucamaranga, Colombia.

 

This acquisition includes a team of experts and significant expenditures spent on an irrigation holding pond, security towers, fencing, etc. to meet the Colombia minister of justice and minister of agriculture requirements.

 

Pursuant to the agreement the Company acquired all of the issued and outstanding shares of Medicolombia in exchange for $700,000 and 4,500,000 shares of Allied. The Company closed and completed the acquisition on February 17, 2020. Medicolombia has subsequently changed its name to Allied Colombia S.A.S.

 

Assumption of contract of purchase and sale of 8999 Jim Bailey Rd.

 

                On November 6, 2018, the Company through AM Biosciences signed an assignment to purchase two separate lots located at 8999 Jim Bailey Road in Kelowna, British Columbia, Canada. The land is zoned I2 General Industrial and allow for “Cannabis Production Facilities” as a principal use.

 

The total commitment for the two parcels of land is CAD$1,942,250 (US$1,457,367) (Lot 1 - $988,550, Lot 2 - CAD$953,700). During the year ended August 31, 2019, the Company executed several “offer to purchase amendments” to defer the assignment and close of the two parcels of land. On November 11, 2019, the Company executed an additional offer to purchase amendment to extend the assignment and close of the land parcels no later than February 10, 2020 and there was an additional amendment to extend the close of the purchase to May 2020. On May 7, 2020, the Company assigned the purchase of Lot 1 to a third party. In June 2020, the Company entered into a lease agreement to lease Lot 1 from the third party for an annual rent of CAD$70,442 for 10 years commencing June 1, 2020 until May 31, 2030.

 

In November 2019, the board of directors determined the Company would not close on Lot 2 as the parcel of land will not be required for future operations. As a result, the Company does not have a commitment to pay the value of CAD$953,700 for the land and will eligible to receive or assign the initial refundable deposit of CAD$10,000. During the year ended August 31, 2020, this contract of purchase and sale for LOT 2 – 8999 Jim Bailey Road was assigned to another non related party.

 

During the three months ended November 30, 2020, the Company terminated the lease. Pursuant to the agreement the Landlord accepts the surrender of the lease and payment of the sum of CAD$176,000 by the Landlord to the Company in return for the Company agreeing to relinquish, transfer and assign to the Landlord, any and all rights either of them has or may have in the site preparation work completed in the current year. Upon the termination of the lease there were no further commitments to this project.

 

Natural Health Products Acquisition

 

In May 2019 the management team of AM Biosciences were able to negotiate the inclusion of a natural health products catalogue of products. This includes 50 products in the natural health vertical market. Three of these products are of particular interest as they have Natural Health Products registration numbers with Health Canada. AM Biosciences can add these to the product offerings both in Canada and the United States.

 

Xtreme Cubes construction has begun

 

In June 2019, AM Biosciences signed the production and manufacturing contract to begin the manufacturing of the full building for the Canada extraction and production facility. This building will be a fully scalable, modular building. This building is expected to come off of the production line in Nevada sometime in the first quarter of 2020. We anticipate being able to extract and produce additional strain development in this building beginning first quarter 2020. The Company made an upfront payment of $230,000 USD in June 2019, an additional payment of $903,385 in August 2019 and an additional payment of $92,000 in March 2020. At November 30, 2020, Company had deposits of $2,585,540 (August 31, 2020 - $2,600,720) to purchase prefabricated buildings. As of November 30, 2020, the Company had not yet received the buildings and the amounts have been recorded as deposits.

 

 
37

Table of Contents

 

Commitments and Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

Off-balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements.

 

Going Concern

 

As reflected in the accompanying financial statements, the Company had an accumulated deficit of approximately $9,104,428 at November 30, 2020 and a working capital deficit of $3,095,035 net loss of $1,195,862.

 

The Company does not yet have a history of financial stability. Historically, the principal source of liquidity has been the issuance of equity securities. In addition, the Company is in the development stage and has generated no revenues since inception. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue operations is dependent on the success of Management’s plans, which include the raising of capital through the issuance of equity securities, until such time that funds provided by operations are sufficient to fund working capital requirements.

 

The Company will require additional funding to finance the growth of its current and expected future operations as well as to achieve its strategic objectives. The Company believes its current available cash will be sufficient to meet its cash needs for the near future. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all.

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Risks

 

As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes of accounting principles generally accepted in the United States.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

 

Our management evaluated the effectiveness of the Company’s internal control over financial reporting as of November 30, 2020. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework. Based on this evaluation, our management concluded that, as of November 30, 2020, our internal control over financial reporting was effective.

 

This quarterly report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permits us to provide only management’s report in this quarterly report.

 

Changes in Internal Control over Financial ReportingThere were no changes in our internal control over financial reporting that occurred during the interim period from September 1, 2020 through November 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 
38

Table of Contents

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties other than the following:

 

On or about April 30, 2020 the Company filed a complaint entitled ALLIED CORP., a Nevada corporation, Plaintiff, v. MALCOLM DAVIDSON, an individual, ANTHONY ZELEN, an individual, and DAVID WEINKAUF, an individual, Defendants, and TACTICAL RELIEF, LLC, a Delaware limited liability company, Nominal Party, filed in the Delaware Chancery Court as Case No. 2020-0321 – PAF (the “Delaware Action”).

 

On or about May 28, 2020 the Company filed that a complaint entitled ALLIED CORP., a Nevada corporation, and AM (ADVANCED MICRO) BIOSCIENCES, INC., an ALLIED CORP., a Nevada corporation, and AM (ADVANCED MICRO) BIOSCIENCES, INC., a British Columbian corporation, Plaintiffs, vs. MALCOLM DAVIDSON, an individual, ANTHONY ZELEN, an individual, and DAVID WEINKAUF, an individual, Defendants filed on May 28, 2020 in the District Court of Clark County Nevada as Case No. A-20-815610-B (The “Nevada Action”, and collectively with the Delaware action the “CLAIMS”).

 

On or about September 30, 2020 but effective September 21, 2020 the parties entered into three separate settlement agreements resolving the claims of both the Delaware Action and the Nevada Action.

 

In December 2018, the Company’s subsidiary AM Biociences had issued 5,000,000 shares of its common stock to both Mr. Zelen and Mr. Weinkauf as an investment at $0.0001cents. These were converted to 4,311,585 shares (the “SECFAC Shares”) of SECFAC Exchange Corp. (“SECFAC”) at the time of the acquisition of AM Biosciences by Allied Corp. Pursuant to the settlement agreements, Mr. Zelen and Mr. Weinkauf both returned 4,061,585 of the SECFAC Shares to be immediately returned to SECFAC’s treasury.

 

Further, in March 2019, Mr. Calum Hughes and each of Mr. Zelen and Mr. Weinkauf entered into an agreement for the sale of 6,250,000 shares of common stock of AM Biosciences to be sold to Mr. Zelen and Mr. Weinkauf from Mr. Calum Hughes for $0.0001cents each (the “Repudiated Shares”). These were issued back to Calum Hughes after the non-payment and issuance of a letter of acceptance of repudiation in April 2020. (the “Repudiation Letter”). As part of the settlement, each of Mr. Zelen and Mr. Weinkauf acknowledged and accepted the repudiation letter.

 

Pursuant to the settlement with Mr. Zelen, Allied agreed to pay through his counsel a total of USD$30,000 as a flat fee settlement cash portion, payable in three installments as follows: a. The first installment of $10,000.00 USD is to be paid on or before October 31, 2020, b. The second installment of $10,000 USD is to be paid on or before November 30, 2020; and c. The third installment of $10,000USD is to be paid on or before December 30, 2020. These payments have not been made as of the date of this report on Form 10-Q.

 

 
39

Table of Contents

  

Pursuant to the settlement with Mr. Weinkauf, Allied agreed to pay through his counsel a total of USD$60,000 as a flat fee settlement cash portion, payable in three installments as follows: a. The first installment of $30,000.00 USD is to be paid on or before October 31, 2020, b. The second installment of $20,000 USD is to be paid on or before November 30, 2020; and c. The third installment of $10,000USD is to be paid on or before December 30, 2020. These payments have not been made as of the date of this report on Form 10-Q.

 

Pursuant to the original settlement with Mr. Davidson, Allied agreed to pay through his counsel a total of USD$15,000 as a flat fee settlement cash portion payable on or before October 31, 2020. This was paid subsequent to the period ending November 30, 2020.

 

In addition, each of the defendants agreed to certain confidentiality and non-solicitation covenants in addition to other terms.

 

Item 1A. Risk Factors.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 2. Unregistered Sales of Securities and Use of Proceeds.

 

On September 21, 2020, the Company issued 80,000 shares to an accredited investor who purchased such shares in a private placement at a purchase price of $1.25 per share for gross cash proceeds of $100,000.

 

On September 30, 2020, the Company issued 120,000 shares to two accredited investors who purchased such shares in a private placement at a purchase price of $1.25 per share for gross cash proceeds of $150,000.

 

On September 29, 2020, the company issued a convertible note with a face value of $163,341.25 and warrants to purchase 130,673 shares of the company’s common stock at $1.25 per share for 2 years. The note is convertible at any time through the date which is 179 days from the date of issuance at a conversion price of $1.25 per share.

 

On October 26, 2020, the company issued a convertible note with a face value of $37,613.17 and warrants to purchase 30,090 shares of the company’s common stock at $1.25 per share for 2 years. The note is convertible at any time through the date which is 179 days from the date of issuance at a conversion price of $1.25 per share.

 

On November 11, 2020, the company issued a convertible note with a face value of $85,937.50 and warrants to purchase 68,750 shares of the company’s common stock at $1.25 per share for 2 years. The note is convertible at any time through the date which is 179 days from the date of issuance at a conversion price of $1.25 per share.

 

On December 2, 2020, the company issued convertible notes to two accredited investors with a face value of $600,000 and warrants to purchase 240,000 shares of the company’s common stock at $1.25 per share for 2 years. The notes are convertible at any time through the date which is 365 days from the date of issuance at a conversion price of $1.25 per share.

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. Mine Safety Disclosures

 

None

 

Item 5. Other Information.

 

 
40

Table of Contents

 

Item 6. Exhibits.

 

31.1

Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer

 

31.2

Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer

 

32.1

Section 1350 Certification of Chief Executive Officer

 

32.2

Section 1350 Certification of Chief Financial Officer

 

101

Interactive data files pursuant to Rule 405 of Regulation S-T.

 

 
41

Table of Contents

  

SIGNATURES*

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Allied Corp.

(Registrant)

 

Date: January 18, 2021

By:

/s/ Calum Hughes

Calum Hughes

Chief Executive Officer and Director

Principal and Executive Officer

 

Date: January 18, 2021

By:

/s/ Ryan Maarschalk

Ryan Maarschalk

Chief Financial Officer

Principal Financial Officer

Principal Accounting Officer

 

 
42

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
5/31/30
11/11/22
10/16/22
9/29/22
10/31/21
5/20/21
5/9/21
4/23/21
3/31/21
3/27/21
1/23/21
Filed on:1/20/21
1/18/21
12/30/20
12/2/20
For Period end:11/30/20NT 10-K,  NT 10-Q
11/20/20
11/11/20
11/1/20
10/31/20
10/26/20
9/30/20
9/29/20
9/21/20
9/1/20
8/31/2010-K,  10-K/A,  NT 10-K
7/20/20
7/1/20
6/30/20
6/20/20
6/1/20
5/29/20
5/28/20
5/7/208-K
4/30/20
2/18/20
2/17/20
2/10/20
1/23/20
11/30/1910-Q,  NT 10-Q
11/11/19
9/10/198-K,  8-K/A
9/1/19
8/31/1910-KT,  NT 10-K
8/30/19
8/29/198-K
8/27/19
7/25/19
7/1/19DEF 14A
12/15/18
11/6/18
4/13/18
1/4/18
2/3/13
 List all Filings 
Top
Filing Submission 0001477932-21-000338   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 25, 1:12:21.1pm ET